WebMar 31, 2024 · Gilead Sciences ( NASDAQ:GILD - Get Rating) last announced its quarterly earnings data on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.17. Gilead Sciences had a return on equity of 44.46% and a net margin of 16.83%. Web1 day ago · This article Expert Ratings for Gilead Sciences originally appeared on Benzinga.com.Weiter zum vollständigen Artikel bei "Benzinga"
Gilead Sciences (GILD) Pe Ratio (TTM) - Zacks.com
WebBeurs : Real time aandelenkoersen op aandelen, indices, valuta, grondstoffen - MarketScreener.com WebGILD Gilead Sciences Inc. Analyst Estimates & Rating – WSJ Gilead Sciences Inc. GILD (U.S.: Nasdaq) View All companies REAL TIME 11:22 AM EDT 04/05/23 $83.29 … combined anterior and posterior colporrhaphy
Gilead Sciences, Inc. Reports Moody
WebDec 15, 2024 · Key rating considerations are summarized below. Gilead's A3 rating reflects its leadership in HIV medications, its high margins, and its strong free cash flow. … WebMar 30, 2010 · Gilead Sciences, Inc., a corporation duly incorporated and subsisting under the laws of the State of Delaware (herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to Cede & Co., or registered assigns, the principal sum of DOLLARS ... Web51 rows · Gilead Sciences, Inc. Ticker: GILD Moody's Org ID: 600057290 LEI: 549300WTZWR07K8MNV44 Market Segment: Corporates Industry: PHARMACEUTICALS: GENERAL & SPECIALTY Peer Group: Pharmaceutical Domicile: United States Please … drug rehab facilities in alaska